Food and Drug Administration (FDA)-approved TNF antagonists (infliximab, etanercept, adalimumab, certolizumab and golimumab) have shown to be extremely efficacious in the treatment of inflammatory diseases presenting with end-stage fibrosis, such as rheumatoid arthritis, spondylarthropathies, Crohn’s disease, and ulcerative colitis. Here, TNF is linked to rheumatoid arthritis.